NR 565 Advanced Pharmacology Week 4 Midterm
Exam Review Question Bank | 200 Questions with
Detailed Rationale & Verified Answers
,Question 1
An Advanced Practice Registered Nurse (APRN) is practicing in a state that grants full
practice authority. Which of the following best describes the regulatory scope of this
APRN's prescriptive authority?
A) The APRN may prescribe non-controlled substances independently but requires a
physician's co-signature for Schedule II–V controlled substances.
B) The APRN's prescriptive authority is granted directly by the Federal Food and Drug
Administration (FDA) rather than a state board.
C) The APRN is legally permitted to evaluate patients, diagnose, order diagnostic tests,
and manage treatments, including prescribing medications, without physician oversight.
D) The APRN must establish a formal collaborative practice agreement with a physician
who reviews 20% of patient charts monthly.
Verified Answer: C
Explanation: Full practice authority allows APRNs to practice, diagnose, and prescribe
medications (including controlled substances, depending on state law) under the
exclusive regulatory authority of the state board of nursing, completely bypassing the
legal requirement for a collaborative practice agreement or physician co-signature.
Options A and D describe reduced or restricted practice environments. Option B is
false; prescriptive authority is a state-level regulatory right, not an FDA mandate.
Question 2
When evaluating a drug's safety profile, the APRN notes that it has a Narrow Therapeutic
Index (NTI). What is the primary clinical implication of an NTI drug?
A) The drug has a prolonged half-life, meaning it only needs to be administered once
every two weeks.
B) The drug requires a loading dose because its therapeutic effects take months to
manifest in plasma.
,C) The difference between the minimum effective concentration and the minimum toxic
concentration is very small, requiring routine therapeutic drug monitoring (TDM).
D) The drug is highly hydrophilic, meaning it does not distribute into lipid-rich tissues or
pass the blood-brain barrier.
Verified Answer: C
Explanation: Narrow Therapeutic Index (NTI) drugs possess a very narrow margin of
safety. Small changes in systemic plasma concentrations can lead to sudden
subtherapeutic failure or severe, life-threatening toxicities. Common examples include
digoxin, lithium, phenytoin, and warfarin. These medications require frequent blood
draws for therapeutic drug monitoring to ensure serum concentrations remain within
the safe window.
Question 3
A patient is prescribed an oral medication that exhibits a high first-pass hepatic extraction
ratio. If the patient is suddenly transitioned to an intravenous (IV) formulation of the
identical drug, how must the dosage be modified?
A) The IV dose must be significantly higher than the oral dose to compensate for the lack
of gastrointestinal absorption.
B) The IV dose must be significantly lower than the oral dose because IV administration
completely bypasses hepatic first-pass metabolism.
C) The IV dose must remain identical to the oral dose because bioavailability is uniform
across all routes of administration.
D) The IV dose must be administered alongside a CYP450 inducer to simulate the liver's
natural metabolic degradation.
Verified Answer: B
Explanation: Oral medications are absorbed through the gastrointestinal tract and
delivered directly to the liver via the portal vein before entering systemic circulation. A
high first-pass extraction ratio means the liver degrades a massive percentage of the
drug before it ever reaches its site of action. Intravenous administration delivers 100%
, of the drug directly into systemic circulation, bypassing this initial hepatic degradation
entirely. Therefore, the IV dose must be substantially lower to avoid immediate systemic
toxicity.
Question 4
A patient presents with an acute overdose of a weak acid drug, such as acetylsalicylic acid
(aspirin). The emergency department clinician initiates an intravenous infusion of sodium
bicarbonate to alkalinize the patient's urine. Which pharmacokinetic phenomenon
explains why this enhances drug elimination?
A) Enzyme induction, which speeds up hepatic Phase I oxidation pathways.
B) Protein binding displacement, which shifts the drug from albumin into tissue stores.
C) Ion trapping, where the alkaline urine converts the weak acid into its ionized state,
preventing its reabsorption across the renal tubular membrane.
D) Biliary excretion acceleration, which forces the drug out via fecal pathways.
Verified Answer: C
Explanation: Ion trapping relies on the principle that ionized (charged) molecules are
water-soluble and cannot readily cross lipid cell membranes, whereas non-ionized
molecules are lipid-soluble and diffuse easily. Aspirin is a weak acid. When the urine
pH is raised (alkalinized) by sodium bicarbonate, the weak acid sheds a proton and
becomes highly ionized. In this charged state, it cannot diffuse back across the renal
tubular epithelial cells into the bloodstream, trapping it in the renal filtrate to be
rapidly excreted in urine.
Question 5
A patient with a history of chronic deep vein thrombosis (DVT) is stabilized on a
maintenance dose of warfarin. The patient is diagnosed with active pulmonary
tuberculosis and is started on a multidrug regimen containing rifampin, a potent
Exam Review Question Bank | 200 Questions with
Detailed Rationale & Verified Answers
,Question 1
An Advanced Practice Registered Nurse (APRN) is practicing in a state that grants full
practice authority. Which of the following best describes the regulatory scope of this
APRN's prescriptive authority?
A) The APRN may prescribe non-controlled substances independently but requires a
physician's co-signature for Schedule II–V controlled substances.
B) The APRN's prescriptive authority is granted directly by the Federal Food and Drug
Administration (FDA) rather than a state board.
C) The APRN is legally permitted to evaluate patients, diagnose, order diagnostic tests,
and manage treatments, including prescribing medications, without physician oversight.
D) The APRN must establish a formal collaborative practice agreement with a physician
who reviews 20% of patient charts monthly.
Verified Answer: C
Explanation: Full practice authority allows APRNs to practice, diagnose, and prescribe
medications (including controlled substances, depending on state law) under the
exclusive regulatory authority of the state board of nursing, completely bypassing the
legal requirement for a collaborative practice agreement or physician co-signature.
Options A and D describe reduced or restricted practice environments. Option B is
false; prescriptive authority is a state-level regulatory right, not an FDA mandate.
Question 2
When evaluating a drug's safety profile, the APRN notes that it has a Narrow Therapeutic
Index (NTI). What is the primary clinical implication of an NTI drug?
A) The drug has a prolonged half-life, meaning it only needs to be administered once
every two weeks.
B) The drug requires a loading dose because its therapeutic effects take months to
manifest in plasma.
,C) The difference between the minimum effective concentration and the minimum toxic
concentration is very small, requiring routine therapeutic drug monitoring (TDM).
D) The drug is highly hydrophilic, meaning it does not distribute into lipid-rich tissues or
pass the blood-brain barrier.
Verified Answer: C
Explanation: Narrow Therapeutic Index (NTI) drugs possess a very narrow margin of
safety. Small changes in systemic plasma concentrations can lead to sudden
subtherapeutic failure or severe, life-threatening toxicities. Common examples include
digoxin, lithium, phenytoin, and warfarin. These medications require frequent blood
draws for therapeutic drug monitoring to ensure serum concentrations remain within
the safe window.
Question 3
A patient is prescribed an oral medication that exhibits a high first-pass hepatic extraction
ratio. If the patient is suddenly transitioned to an intravenous (IV) formulation of the
identical drug, how must the dosage be modified?
A) The IV dose must be significantly higher than the oral dose to compensate for the lack
of gastrointestinal absorption.
B) The IV dose must be significantly lower than the oral dose because IV administration
completely bypasses hepatic first-pass metabolism.
C) The IV dose must remain identical to the oral dose because bioavailability is uniform
across all routes of administration.
D) The IV dose must be administered alongside a CYP450 inducer to simulate the liver's
natural metabolic degradation.
Verified Answer: B
Explanation: Oral medications are absorbed through the gastrointestinal tract and
delivered directly to the liver via the portal vein before entering systemic circulation. A
high first-pass extraction ratio means the liver degrades a massive percentage of the
drug before it ever reaches its site of action. Intravenous administration delivers 100%
, of the drug directly into systemic circulation, bypassing this initial hepatic degradation
entirely. Therefore, the IV dose must be substantially lower to avoid immediate systemic
toxicity.
Question 4
A patient presents with an acute overdose of a weak acid drug, such as acetylsalicylic acid
(aspirin). The emergency department clinician initiates an intravenous infusion of sodium
bicarbonate to alkalinize the patient's urine. Which pharmacokinetic phenomenon
explains why this enhances drug elimination?
A) Enzyme induction, which speeds up hepatic Phase I oxidation pathways.
B) Protein binding displacement, which shifts the drug from albumin into tissue stores.
C) Ion trapping, where the alkaline urine converts the weak acid into its ionized state,
preventing its reabsorption across the renal tubular membrane.
D) Biliary excretion acceleration, which forces the drug out via fecal pathways.
Verified Answer: C
Explanation: Ion trapping relies on the principle that ionized (charged) molecules are
water-soluble and cannot readily cross lipid cell membranes, whereas non-ionized
molecules are lipid-soluble and diffuse easily. Aspirin is a weak acid. When the urine
pH is raised (alkalinized) by sodium bicarbonate, the weak acid sheds a proton and
becomes highly ionized. In this charged state, it cannot diffuse back across the renal
tubular epithelial cells into the bloodstream, trapping it in the renal filtrate to be
rapidly excreted in urine.
Question 5
A patient with a history of chronic deep vein thrombosis (DVT) is stabilized on a
maintenance dose of warfarin. The patient is diagnosed with active pulmonary
tuberculosis and is started on a multidrug regimen containing rifampin, a potent
